Latest Period
Q4 2025
Security Snapshot
Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX) Institutional Ownership
CUSIP: 47103J105
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
172
Shares (Excl. Options)
62,149,256
Price
$13.80
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- JANX on Nasdaq
- Shares outstanding
- 61,395,180
- Price per share
- $13.90
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 62,149,256
- Total reported value
- $857,685,756
- % of total 13F portfolios
- 0%
- Share change
- -2,658,639
- Value change
- -$103,940,615
- Number of holders
- 172
- Price from insider filings
- $13.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- JANX - Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 47103J105.
- 172 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 172 to 37 between Q4 2025 and Q1 2026.
- Reported value moved from $857,685,756 to $10,149,181.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 172 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 47103J105?
CUSIP 47103J105 identifies JANX - Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 47103J105:
Significant Owners of Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20% | $383,922,060 | 11,971,377 | RA Capital Management, L.P. | 06 Mar 2025 | |||
| JANUS HENDERSON GROUP PLC | 8.9% | -11% | $73,836,251 | -$9,432,245 | 5,350,453 | -11% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| STATE STREET CORP | 6.4% | $53,184,524 | 3,853,951 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| FMR LLC | 5.8% | $48,484,949 | 3,512,384 | FMR LLC | 31 Dec 2025 | |||
| BlackRock, Inc. | 5.7% | $77,284,838 | 3,345,664 | BlackRock, Inc. | 30 Jun 2025 | |||
| Prosight Management, LP | 5.3% | $43,569,636 | 3,157,220 | W. Lawrence Hawkins | 03 Feb 2026 | |||
| Point72 Asset Management, L.P. | 5% | $42,669,650 | 3,069,759 | Point72 Asset Management, L.P. | 28 Apr 2026 | |||
| Paradigm Biocapital Advisors LP | 4.9% | -18% | $73,444,489 | -$14,982,559 | 2,920,258 | -17% | Paradigm BioCapital Advisors LP | 30 Jun 2025 |
| Adage Capital Management, L.P. | 4.3% | -21% | $63,503,750 | -$13,499,262 | 2,525,000 | -18% | Adage Capital Management, L.P. | 30 Jun 2025 |
As of 31 Dec 2025, 172 institutional investors reported holding 62,149,256 shares of Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX). This represents 101% of the company’s total 61,395,180 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 18% | 11,189,693 | 0% | 1.6% | $154,417,763 |
| JANUS HENDERSON GROUP PLC | 8.7% | 5,350,453 | +14% | 0.03% | $73,850,341 |
| BlackRock, Inc. | 6.6% | 4,080,200 | +9.4% | 0% | $56,306,760 |
| STATE STREET CORP | 6.3% | 3,853,951 | +104% | 0% | $53,184,524 |
| FMR LLC | 5.7% | 3,512,384 | -61% | 0% | $48,470,898 |
| VANGUARD GROUP INC | 4.7% | 2,906,386 | +20% | 0% | $40,108,126 |
| Prosight Management, LP | 3.9% | 2,392,523 | +176% | 6.8% | $33,016,817 |
| ORBIMED ADVISORS LLC | 3.2% | 1,954,426 | +11% | 0.58% | $26,971,079 |
| TCG Crossover Management, LLC | 2.9% | 1,789,617 | 0.82% | $24,696,715 | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.6% | 1,610,186 | +130% | 0% | $22,220,567 |
| Alyeska Investment Group, L.P. | 2.1% | 1,301,089 | +206% | 0.05% | $17,955,028 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,113,582 | +2.7% | 0% | $15,370,581 |
| CITADEL ADVISORS LLC | 1.8% | 1,104,144 | +38% | 0.01% | $15,237,187 |
| GOLDMAN SACHS GROUP INC | 1.7% | 1,073,656 | +64% | 0% | $14,816,453 |
| Woodline Partners LP | 1.7% | 1,027,221 | +0.03% | 0.05% | $14,175,650 |
| Logos Global Management LP | 1.6% | 1,000,000 | +7% | 0.92% | $13,800,000 |
| Point72 Asset Management, L.P. | 1.6% | 961,819 | -44% | 0.02% | $13,273,102 |
| READYSTATE ASSET MANAGEMENT LP | 1.4% | 885,895 | -7.8% | 0.54% | $12,225,351 |
| Balyasny Asset Management L.P. | 1.4% | 885,551 | 0.02% | $12,220,604 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.2% | 744,466 | -41% | 0% | $10,274,000 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 738,330 | +50% | 0% | $10,188,954 |
| Cormorant Asset Management, LP | 1.1% | 650,000 | -24% | 0.51% | $8,970,000 |
| MORGAN STANLEY | 1% | 618,385 | +25% | 0% | $8,533,727 |
| UBS Group AG | 0.96% | 590,060 | +51% | 0% | $8,142,828 |
| JANE STREET GROUP, LLC | 0.88% | 540,233 | +564% | 0.01% | $7,455,216 |
Institutional Holders of Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 733,915 | $10,149,181 | -$1,115,716 | $13.90 | 37 |
| 2025 Q4 | 62,149,256 | $857,685,756 | -$103,940,615 | $13.80 | 172 |
| 2025 Q3 | 65,065,945 | $1,590,036,358 | -$3,819,977 | $24.44 | 170 |
| 2025 Q2 | 65,389,958 | $1,510,522,459 | -$28,053,981 | $23.10 | 169 |
| 2025 Q1 | 66,482,175 | $1,805,570,973 | -$17,647,630 | $27.00 | 179 |
| 2024 Q4 | 64,089,510 | $3,430,809,553 | +$1,001,839,547 | $53.54 | 213 |
| 2024 Q3 | 45,621,730 | $2,072,353,785 | +$42,332,014 | $45.43 | 158 |
| 2024 Q2 | 44,723,442 | $1,873,142,325 | +$107,659,314 | $41.89 | 153 |
| 2024 Q1 | 42,327,541 | $1,593,608,078 | +$334,250,630 | $37.65 | 118 |
| 2023 Q4 | 33,501,695 | $359,539,970 | -$17,204,195 | $10.73 | 64 |
| 2023 Q3 | 35,112,124 | $353,984,587 | +$45,518,472 | $10.08 | 57 |
| 2023 Q2 | 30,508,831 | $362,117,070 | -$408,523 | $11.87 | 54 |
| 2023 Q1 | 30,541,873 | $369,527,936 | +$18,629,245 | $12.10 | 48 |
| 2022 Q4 | 28,954,042 | $381,308,644 | -$7,758,264 | $13.17 | 49 |
| 2022 Q3 | 29,548,436 | $400,093,845 | +$8,918,649 | $13.54 | 45 |
| 2022 Q2 | 28,911,820 | $352,963,471 | +$6,297,905 | $12.21 | 43 |
| 2022 Q1 | 28,388,419 | $407,113,023 | +$11,406,319 | $14.34 | 46 |
| 2021 Q4 | 27,496,946 | $541,627,745 | +$19,103,067 | $19.73 | 46 |
| 2021 Q3 | 26,499,088 | $571,208,440 | +$35,499,490 | $21.63 | 44 |
| 2021 Q2 | 24,743,225 | $614,460,000 | +$614,460,000 | $24.95 | 29 |